Synthesis and evaluation of 177Lu-labeled anti-EGFR Fab antibody for lung cancer

被引：1
作者：
Li, Yuan-Yuan [1 ,2 ]
Yu, Jia-Yan [1 ,2 ]
Wang, Tao [1 ,2 ]
Wang, Jing [2 ,3 ]
Zhao, Peng [2 ,3 ]
Yang, Xia [2 ,3 ]
Wei, Hong-Yuan [2 ,4 ]
Chen, Yue [1 ,4 ]
机构：
[1] Southwest Med Univ, Dept Nucl Med, Affiliated Hosp, Luzhou 646000, Peoples R China
[2] China Acad Engn Phys, Inst Nucl Phys & Chem, Mianyang 621900, Peoples R China
[3] Lab Targeted Radiopharmaceut Creat, Mianyang 621900, Peoples R China
[4] Key Lab Nucl Med & Mol Imaging Sichuan Prov, Luzhou 646000, Peoples R China
来源：
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY | 2025年 / 334卷 / 03期
基金：
中国国家自然科学基金;
关键词：
Fab fragments; Lutetium-177; Anti-EGFR antibody; Biodistribution; Lung cancer; SQUAMOUS-CELL CARCINOMA; TARGETED THERAPY; RADIOIMMUNOTHERAPY; BIODISTRIBUTION; NECK; HEAD;
D O I：
10.1007/s10967-025-10030-4
中图分类号：
O65 [分析化学];
学科分类号：
070302 ; 081704 ;
摘要：
Fab fragments obtained via enzymatic digestion of full-length antibodies or by gene recombination technology have smaller molecular weight and greater penetration ability. Those advantages make it uniquely suited to deliver radionuclides. In this study, we prepared a Fab fragment from the anti-EGFR antibody Cetuximab and labeled it with 177Lu. The binding activity in vitro and biodistribution in vivo of [177Lu]Lu-DOTA-Fab-Cetuximab were investigated. The [177Lu]Lu-labeled Fab fragment showed improved tumor penetration and faster blood clearance compared to the full-length antibody.
引用
收藏
页码：2139 / 2149
页数：11
相关论文
共 31 条
[1]   SARS-CoV-2 seroprevalence determination in pets and camels in Egypt using multispecies enzyme-linked immunosorbent assay [J].
Ahmed-Hassan, Hanaa ;
Farouk, Manar M. ;
Ali, M. E. ;
Elsafiee, Esraa A. ;
Hagag, Naglaa ;
Abdelkader, Fatma .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2024, 267
[2]   Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives [J].
Alsadi, Rahaf ;
Djekidel, Mehdi ;
Bouhali, Othmane ;
Doherty, Jim O' .
FRONTIERS IN PHYSICS, 2022, 10
[3]  
BAXTER LT, 1995, CANCER RES, V55, P4611
[4]   Monoclonal antibody-based targeted therapy in breast cancer: Current status and future directions [J].
Bernard-Marty, Chantal ;
Lebrun, Fabienne ;
Awada, Ahmad ;
Piccart, Martine J. .
DRUGS, 2006, 66 (12) :1577-1591
[5]   Key cancer cell signal transduction pathways as therapeutic targets [J].
Bianco, RB ;
Melisi, D ;
Ciardiello, F ;
Tortora, G .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (03) :290-294
[6]   How lmmunoglobulin G Antibodies Kill Target Cells: Revisiting an Old Paradigm [J].
Biburger, Markus ;
Lux, Anja ;
Nimmerjahn, Falk .
ADVANCES IN IMMUNOLOGY, VOL 124, 2014, 124 :67-+
[7]   Cetuximab - A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer [J].
Blick, Stephanie K. A. ;
Scott, Lesley J. .
DRUGS, 2007, 67 (17) :2585-2607
[8]   Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates [J].
Caliceti, P ;
Veronese, FM .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) :1261-1277
[9]   EXPRESSION AND FUNCTION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN PHYSIOLOGY AND DISEASE [J].
Chen, Jianchun ;
Zeng, Fenghua ;
Forrester, Steven J. ;
Eguchi, Satoru ;
Zhang, Ming-Zhi ;
Harris, Raymond C. .
PHYSIOLOGICAL REVIEWS, 2016, 96 (03) :1025-1069
[10]   TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life [J].
Dave, Emma ;
Durrant, Oliver ;
Dhami, Neha ;
Compson, Joanne ;
Broadbridge, Janice ;
Archer, Sophie ;
Maroof, Asher ;
Whale, Kevin ;
Menochet, Karelle ;
Bonnaillie, Pierre ;
Barry, Emily ;
Wild, Gavin ;
Peerboom, Claude ;
Bhatta, Pallavi ;
Ellis, Mark ;
Hinchliffe, Matthew ;
Humphreys, David P. ;
Heywood, Sam P. .
MABS, 2023, 15 (01)
1234